27 April 2023
Business Update and Unaudited Results
Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company focused on the commercialisation of its innovative oral iron therapy for iron deficiency, Accrufer®/Feraccru® (ferric maltol), announces its unaudited preliminary results for the year ended 31 December 2022 and reports a business update covering recent developments, including significant Q1 2023 Accrufer® growth.
Shield’s Chief Executive Officer, Greg Madison, commented: “It has been an extremely busy and productive first quarter of 2023 as we focused our attention on the implementation of our new agreement with Viatris. Creating brand new sales territories and the recruiting, hiring and training of our 50 sales representatives and new managers has been our primary focus. Our internal team has done an amazing job, and I am extremely pleased that not only are we on track for completion of our stated goal by early May, but by the quality and experience of the people we have been able to attract and hire into our organisation.
For further details click here.